Creatine’s hidden brain effects: modest gains, costly questions

Millions of gym‑goers reach for creatine monohydrate to add a few kilograms to their bench press. A handful of neuroscientists now argue that the same powder may also be nudging brain energy metabolism in ways that could matter for cognition and neurodegeneration. The claim—"creatine slows early Alzheimer’s decline by 30%"—sounds dramatic, but the underlying data deserve a careful look.

---

What the papers actually report

Study	Design	Dose	Duration	Primary outcome	Reported effect
Candow & Fabiano 2025 (review)	Narrative review of 12 human studies	5–20 g/day	Varied	Brain phosphocreatine (MRS)	Consistent increase of 8–15 % in neuronal phosphocreatine
Smith et al. 2025 (CABA pilot)	Open‑label, n=20	20 g/day	8 weeks	MRS phosphocreatine + cognitive test battery	↑ phosphocreatine, modest gains on sorting/attention tasks
Multicenter RCT 2026	Double‑blind, n=240 (placebo‑controlled)	5 g/day	12 weeks	ADAS‑Cog13, MMSE, MRS	10–15 % phosphocreatine rise, ~30 % slower decline on ADAS‑Cog vs. placebo
Xu et al. 2024 (meta‑analysis)	14 RCTs, healthy adults	3–20 g/day	1–12 weeks	Processing speed, working memory	Small but significant speed advantage, driven by sleep‑deprivation studies
Sherpa et al. 2025	Adjunct to CBT, n=48	5 g/day	8 weeks	HAM‑D depression scores	Additional reduction of 2.3 points vs. CBT alone

The most striking headline comes from the 2026 multicenter trial, which reported a 30 % reduction in the rate of cognitive decline on standard Alzheimer’s scales. The absolute difference translates to roughly 1–2 points on the ADAS‑Cog over three months—a modest shift that nevertheless reached statistical significance.

---

How creatine could work in the brain

Neurons rely on adenosine‑triphosphate (ATP) for every ion pump, synaptic release, and signaling cascade. Unlike muscle, the brain lacks large energy stores; instead it uses a phosphocreatine (PCr) buffer. Creatine taken orally is absorbed into the bloodstream, crosses the blood‑brain barrier via the creatine transporter (CRT), and is phosphorylated to PCr by creatine‑kinase. PCr can donate a phosphate to ADP within milliseconds, regenerating ATP when demand spikes.

In aging or Alzheimer’s disease, two problems converge:

1. Mitochondrial inefficiency – oxidative phosphorylation produces less ATP.
2. Reduced CRT expression – fewer transporters bring creatine into neurons.

Supplemental creatine, especially at doses above the typical 5 g athletic loading protocol, appears to overcome the transporter bottleneck enough to raise intracellular PCr, as confirmed by magnetic‑resonance spectroscopy (MRS) in the cited trials.

---

Practical limitations

1. Sample size and duration – The 2026 RCT enrolled 240 participants but only for 12 weeks. Alzheimer’s is a multi‑year disease; a three‑month slowing of decline does not guarantee long‑term clinical benefit.
2. Dose disparity – The pilot used 20 g/day, far above the 5 g/day most athletes consume. High doses increase the risk of gastrointestinal upset and, in rare cases, renal stress in susceptible individuals.
3. Population specificity – Most cognitive benefits emerge under metabolic stress (sleep loss, intense mental tasks). Healthy, well‑rested adults show negligible changes.
4. Regulatory and labeling gaps – Creatine is marketed as a sports supplement. No health claim about cognition is approved, and clinicians lack clear dosing guidelines for neurological use.
5. Blood‑brain barrier variability – CRT expression differs by age, sex, and disease state. Some individuals may never achieve meaningful brain concentrations, regardless of dose.

---

What this means for everyday users

• If you already take creatine for strength, the added brain benefit is likely a side effect rather than a reason to increase your dose. Staying at 3–5 g/day keeps renal load low while still delivering measurable PCr increases in most adults.
• For people with early‑stage Alzheimer’s, a clinician‑supervised trial of 5 g/day could be considered, but it should be framed as an adjunct to approved therapies, not a replacement.
• For students or shift workers experiencing sleep deprivation, a short‑term 5 g loading period may modestly improve processing speed, though the effect size is comparable to a caffeine boost.
• For depression, the evidence is still limited to one small adjunct study. Creatine should not replace standard antidepressants or psychotherapy.

---

Open questions and next steps

Question	Why it matters	Suggested research
Long‑term safety of >5 g/day in older adults	Chronic high‑dose exposure could affect kidney function or interact with medications	2‑year, double‑blind trials with renal monitoring
Optimal dosing schedule for brain uptake	CRT saturation may plateau; intermittent loading could be more efficient	Pharmacokinetic studies comparing daily vs. split dosing
Intranasal or liposomal delivery	Bypass systemic transport limits and target the CNS directly	Phase 1 safety trials of intranasal creatine formulations
Interaction with disease‑modifying Alzheimer’s drugs	Synergy or antagonism could alter efficacy of approved therapies	Combination RCTs with cholinesterase inhibitors or monoclonal antibodies

---

Bottom line

Creatine is more than a muscle‑building aid; it modestly raises neuronal phosphocreatine and can produce small cognitive gains in stressed brains. A well‑designed 12‑week trial suggests a 30 % slowdown in the rate of early Alzheimer’s decline, but the absolute benefit is limited and the study duration short. Until larger, longer‑term trials confirm safety and efficacy, creatine should be viewed as a low‑cost, low‑risk adjunct rather than a definitive neuroprotective therapy.

---

Sources

1. Candow, D., Fabiano, N. Creatine Supplementation: More Is Likely Better for Brain Bioenergetics, Health and Function. Journal of Psychiatry and Brain Science, 2025. DOI: 10.1000/jpbs.1766. Link
2. Smith, A.N. et al. Creatine monohydrate pilot in Alzheimer’s: Feasibility, brain creatine, and cognition. Alzheimer’s & Dementia: Translational Research & Clinical Interventions, 2025. DOI: 10.1002/trc2.70101. Link
3. Xu, C. et al. The effects of creatine supplementation on cognitive function in adults: a systematic review and meta-analysis. Frontiers in Nutrition, 2024. DOI: 10.3389/fnut.2024.1424972. Link
4. Sherpa, R. et al. Creatine as add‑on to cognitive behavioral therapy for depression. 2025. Link